Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
PredxBio logo — Reimagining Cancer Care with AI-Driven Spatial Biomarkers

PredxBio

Reimagining Cancer Care with AI-Driven Spatial Biomarkers

Founded 2017 United States Pittsburgh, United States 14 employees Convertible Note Total: $1.67M AI, Biopharma +3

General Information

Company Name PredxBio
Founded Year 2017
Location United States Pittsburgh, United States
Founders / Decision Makers
Team member
Employees 14
Industries AI, Biopharma, Biotechnology +2
Funding Stage Convertible Note
Social

BounceWatch is an independent company data service, not affiliated with PredxBio. To contact PredxBio, visit predxbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does PredxBio compare?

A PDF of PredxBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting PredxBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About PredxBio

SpIntellx is a biotech startup founded in 2017 and headquartered in the United States. The company specializes in the convergence of unbiased spatial analytics and explainable AI to revolutionize precision pathology. By providing novel insights into intermediate cell types, functional states, and cell communications, SpIntellx's solutions empower clinicians and researchers to accelerate drug discovery, optimize clinical trials, and personalize therapeutic options. The company recently secured a Convertible Note investment on 28 February 2023 from notable investors including Keiretsu Capital and Innovation Works. SpIntellx's innovative approach and potential for enhancing drug development and clinical workflows make it an intriguing prospect for venture capital investment in the biopharma and biotechnology industries. With its focus on advancing companion diagnostics and improving personalized treatment options, SpIntellx presents a promising opportunity for investors seeking to support cutting-edge advancements in the healthcare sector. For VC firms looking to back groundbreaking technologies with the potential to shape the future of pathology and therapeutics, SpIntellx's pioneering work in spatial analytics and AI offers an exciting avenue for investment.

Business keywords: Precision Pathology, Spatial Analytics, Explainable AI, Drug Discovery, Clinical Trials, Companion Diagnostics, Personalized Medicine, Computational Pathology, Digital Pathology, Therapeutic Strategies, Pathology, Clinical Workflows

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note Undisclosed 2
Keiretsu Capital Innovation Works
Keiretsu Capital, Innovation Works
28 Feb 2023
Seed Round Undisclosed 1
Innovation Works
Innovation Works
27 Apr 2022
Seed Round $50.00K 2
Innovation Works AlphaLab Health
Innovation Works, AlphaLab Health
12 Mar 2021
Seed Round $260.00K -
02 Feb 2021
Seed Round $463.26K -
13 Aug 2020
Seed Round $275.00K -
06 Aug 2019
Grant $225.00K 1
National Science Foundation
National Science Foundation
08 Feb 2019
Seed Round $300.00K 1
Newlin Investment Company
Newlin Investment Company
10 Sep 2018
Debt Financing $100.00K -
06 Sep 2018

PredxBio Alternatives & Competitors

View All Alternatives
PredxBio vs
Aignostics
Aignostics Germany

AI-powered tissue analysis, validated by pathologists

Series B
106 employees
AI, Health Care
Compare PredxBio vs Aignostics
PredxBio vs
Ibex Medical Analytics
Ibex Medical Analytics United States

Pioneering AI-based cancer diagnostics in pathology

Series C
97 employees
AI, Analytics
PredxBio vs
Parallel Bio
Parallel Bio United States

Using the immune system to cure disease.

Series A
27 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About PredxBio

Reimagining Cancer Care with AI-Driven Spatial Biomarkers
PredxBio was founded in 2017.
PredxBio is headquartered in Pittsburgh, United States.
PredxBio operates in AI, Biopharma, Biotechnology, Life Sciences and Machine Learning. Its work centres on Precision Pathology, Spatial Analytics, Explainable AI and Drug Discovery.
PredxBio has approximately 14 employees.
PredxBio has completed 9 funding rounds, raising a total of $1.67M. The latest funding stage is Convertible Note.
Top alternatives and competitors to PredxBio include Aignostics, Ibex Medical Analytics, Parallel Bio, AlphaBiomics, Theramir Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PredxBio and Aignostics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for PredxBio, https://bouncewatch.com/company/spintellx, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes